- 著者
- Motonobu Saito Tomoyuki Momma Koji Kono
- 出版者
- THE FUKUSHIMA SOCIETY OF MEDICAL SCIENCE
- 雑誌
- FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (ISSN:00162590)
- 巻号頁・発行日
- vol.64, no.1, pp.9-14, 2018 (Released:2018-04-17)
- 参考文献数
- 27
- 被引用文献数
- 16
Targeted therapy against actionable gene mutations shows a significantly higher response rate as well as longer survival compared to conventional chemotherapy, and has become a standard therapy for many cancers. Recent progress in next-generation sequencing (NGS) has enabled to identify huge number of genetic aberrations. Based on sequencing results, patients recommend to undergo targeted therapy or immunotherapy. In cases where there are no available approved drugs for the genetic mutations detected in the patients, it is recommended to be facilitate the registration for the clinical trials. For that purpose, a NGS-based sequencing panel that can simultaneously target multiple genes in a single investigation has been used in daily clinical practice. To date, various types of sequencing panels have been developed to investigate genetic aberrations with tumor somatic genome variants (gain-of-function or loss-of-function mutations, high-level copy number alterations, and gene fusions) through comprehensive bioinformatics. Because sequencing panels are efficient and cost-effective, they are quickly being adopted outside the lab, in hospitals and clinics, in order to identify personal targeted therapy for individual cancer patients.
- 著者
- Kosaku Mimura Leo Yamada Daisuke Ujiie Suguru Hayase Takeshi Tada Hiroyuki Hanayama Aung Kyi Thar Min Masahiko Shibata Tomoyuki Momma Zenichiro Saze Shinji Ohki Koji Kono
- 出版者
- THE FUKUSHIMA SOCIETY OF MEDICAL SCIENCE
- 雑誌
- FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (ISSN:00162590)
- 巻号頁・発行日
- pp.2018-09, (Released:2018-07-27)
- 参考文献数
- 48
- 被引用文献数
- 27
Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC.